Fourth Quarter 2020 Year-Over-Year:
- Product Sales increased 26% to $7.3 billion, primarily due to Veklury® (remdesivir) -
- Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 -

Full Year 2020 Year-Over-Year:
- Product Sales increased 10% to $24.4 billion, primarily due to Veklury -
- Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 -
- Returned $5.0 billion of cash to shareholders through dividends and share repurchases -

Full Year 2021 Guidance:
- Product Sales including Veklury of $23.7 billion to $25.1 billion -
- Operating expenses flat to low single-digit percentage decline -
- Non-GAAP Diluted EPS of $6.75 to $7.45 -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020.

“Gilead continues to play a central role in the pandemic, with Veklury now treating one in two hospitalized patients in the United States. At the same time, we continue to meet the needs of people living with HIV, cancer, viral hepatitis and other conditions,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These new opportunities, together with our continued leadership in antivirals put Gilead on a clear path to growth.”

Financial Results
Three Months Ended Twelve Months Ended December 31, December 31,
(In millions, except percentages, per share amounts)
2020 2019 Change 2020 2019 Change
Product sales excluding Veklury sales $5,390 $5,796 (7)% $21,544 $22,119 (3)%
see & read mkore on
https://www.gilead.com/news-and-press/press-room/press-releases/2021/2/gilead-sciences-announces-fourth-quarter-and-full-year-2020-financial-results